Development and use of in vitro alternatives to animal testing by the pharmaceutical industry 1980–2013
| Knowledge Source Identification | |
|---|---|
| Knowledge source name | Development and use of in vitro alternatives to animal testing by the pharmaceutical industry 1980–2013 |
| Owner/Developer | Toxicology Research |
| Country | United Kingdom |
| Languages | English |
| URL | http://pubs.rsc.org/en/content/articlehtml/2015/tx/c5tx00123d |
| Description | We examined the use of in vitro (including in silico) techniques in preclinical safety testing by the pharmaceutical industry between 1980 and 2013 to determine patterns, drivers and challenges in uptake. Data were collected via a survey sent to the Association of the British Pharmaceutical Industry (ABPI) member companies from the Nonclinical and Biological Discovery Expert Network (NaBDEN) requesting the number of compounds screened using in vitro and in silico tests at 5-year intervals between 1980 and 2005 then yearly from 2008 onwards. [...] In summary, the data show a large increase and a continuing upwards trend in development and adoption of in vitro alternatives to animal testing in pharmaceutical drug development providing new opportunities to improve success rates coupled with a strong commitment to the 3Rs. |
| Knowledge Source Category | |
| Category | Publication |
| Sub categories | Review / Research article |
| Knowledge Dissemination and Sharing | |
| Dissemination channel | Website, Printed |
| Targeted audience (specified/objective analysis) | Scientists, Industry, Researchers |
| Users access | Open access |
| Knowledge Characterization | |
| 3Rs relevance | Replacement, Reduction, Refinement |
| Purpose | Documentation and information |
| Legislative framework | Medicines legislation |
| Technology/Tools | Alternative test methods (in vitro), Non-testing methods (in silico) |